Gabapentin for Sleep in Critically Ill Patients
-
- STATUS
- Recruiting
-
- days left to enroll
- 60
-
- participants needed
- 80
-
- sponsor
- Tufts Medical Center
Summary
Sleep disruption in the intensive care unit (ICU) is a common comorbidity associated with patient morbidity and distress. There are no recommended pharmacologic interventions for sleep promotion, and many pharmacologic solutions may actually increase the risk of adverse outcomes rather than impart benefits. Gabapentin, an anticonvulsant with applications in neuropathic pain, has been investigated for sleep promotion in various populations of outpatients. Here investigators propose a pilot study of gabapentin as a therapy for sleep disruption in the ICU. Outcomes measured will be sleep quality as measured by RCSQ (Richards-Campbell Sleep Questionnaire), wrist actigraphy, EEG, and BIS monitoring. The goal is to enroll 80 critically ill patients, 40 intubated and 40 non-intubated patients. The study will take place over 2 nights, with baseline sleep measurements occurring on the first night and gabapentin administration with repeat sleep measurements on the second night.
Description
Sleep disruption in the intensive care unit (ICU) is a common comorbidity. In addition to being a source of emotional distress for many patients, sleep disturbance may be associated with ICU delirium, prolonged need for respiratory support, and immune and neurocognitive dysfunction. Since sleep is a potentially modifiable risk factor for ICU outcomes, there has been increased interest in sleep study and promotion in critically ill patients, as evidenced by the inclusion of sleep disruption in the 2018 Society of Critical Care Medicine Clinical Practice Guidelines. Although these Guidelines make soft recommendations for non-pharmacologic strategies to improve sleep in this patient population, these strategies are often lacking in efficacy and/or evidence. There are no recommended pharmacologic interventions for sleep promotion, and many pharmacologic solutions may actually increase the risk of adverse outcomes rather than impart benefits.
Gabapentin, an anticonvulsant with applications in neuropathic pain, has been investigated for sleep promotion in various populations of outpatients. In non-ICU patients, gabapentin is an effective therapy for insomnia in patients with restless leg syndrome or chronic neuropathy. Even in patients without these comorbidities, gabapentin has shown efficacy compared with placebo in improving sleep duration and depth. Gabapentin has several advantages compared to common sedatives used in the ICU, including no increased day drowsiness, no QTc prolongation, and some studies suggesting no association with delirium, particularly when used in a daily dose < 600 mg. Although caution must be used in dosing this drug in patients with renal dysfunction, a dose of up to 300 mg daily may be used if CrCl < 15 ml/m, and doses of up to 300 mg after hemodialysis (HD) have been used safely in patients with end stage renal disease (ESRD). Additionally, its generic status and broad therapeutic index make it a cost-effective and attractive agent for further study and use.
Here investigators propose a pilot study of gabapentin as a therapy for sleep disruption in the ICU. To date, there have been no studies of gabapentin use for sleep in the ICU; this study would represent the first of its kind. Given the magnitude of the problem represented by sleep disruption in the ICU, the ability of gabapentin to mitigate insomnia in outpatients, and the low side effect profile and wide therapeutic window of gabapentin, studying the effects of gabapentin on sleep disruption in the ICU is a logical and potentially practice changing step.
Details
| Condition | Intensive Care Unit Sleep Disruption |
|---|---|
| Treatment | Gabapentin 300 mg PO at 8 PM |
| Clinical Study Identifier | NCT04631510 |
| Sponsor | Tufts Medical Center |
| Last Modified on | 17 March 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer